Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Subscribe To Our Newsletter & Stay Updated
